Ultragenyx Advances Five Rare Disease Therapies in 2025
Event summary
- Ultragenyx advanced five investigational therapies in pivotal clinical programs with potential to reach tens of thousands of patients globally.
- The company invested 62% of operating expenses in R&D, focusing on rare and ultra-rare diseases.
- Ultragenyx supported over 700 patients in 50 countries through expanded access and patient assistance programs since 2013.
- Achieved 92% employee engagement survey participation with an overall score of 86%.
- Approved $3.3 million in charitable donations across more than 20 countries.
The big picture
Ultragenyx's 2025 Impact Report underscores the company's strategic focus on accelerating rare disease therapies while expanding patient access and corporate sustainability. The biopharmaceutical sector is increasingly prioritizing ESG metrics, with Ultragenyx positioning itself as a leader in both therapeutic innovation and responsible business practices.
What we're watching
- Pipeline Progress
- How Ultragenyx's Dynamic Development Model will accelerate clinical trial timelines and patient access.
- Regulatory Advocacy
- Whether the Act for Ultra-Rare initiative can drive meaningful policy changes for ultra-rare disease treatments.
- Sustainability Commitments
- The pace at which Ultragenyx scales its environmental initiatives across global operations.
Related topics